| Identification | Back Directory | [Name]
(2R)-1,1,1-trifluoro-2-[4-[(2S)-2-[[(3S)-3-methylmorpholin-4-yl]methyl]-4-thiophen-2-ylsulfonylpiperazin-1-yl]phenyl]propan-2-ol | [CAS]
1361217-07-3 | [Synonyms]
AMG-1694
AMG-1694
(AMG1694)
(2R)-1,1,1-trifluoro-2-[4-[(2S)-2-[[(3S)-3-methylmorpholin-4-yl]methyl]-4-thiophen-2-ylsulfonylpiperazin-1-yl]phenyl]propan-2-ol | [Molecular Formula]
C23H30F3N3O4S2 | [MDL Number]
MFCD28411405 | [MOL File]
1361217-07-3.mol | [Molecular Weight]
533.63 |
| Chemical Properties | Back Directory | [Boiling point ]
652.6±65.0 °C(Predicted) | [density ]
1.348±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
12.89±0.15(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Description]
AMG-1694 is a potent GK-GKRP disruptor. | [Uses]
AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC50 of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals[1]. | [References]
[1] Lloyd DJ, et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature. 2013 Dec 19;504(7480):437-40. DOI:10.1038/nature12724 |
|
|